Navigation Links
Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
Date:3/13/2008

share-based compensation expenses, as well as legal,

facilities, and marketing expenses as compared with the prior-year

quarter.

-- Cash and cash equivalents were $97.7 million as of December 31, 2007,

compared with $44.2 million as of December 31, 2006 and $105.1

million as of September 30, 2007.

Financial Outlook for 2008

The Company anticipates 2008 cash expenses of approximately $40 million to $50 million, depending on the progress of various pre-clinical and clinical programs and the timing of its manufacturing scale up.

Conference Call

Halozyme management will host a pipeline update conference call tomorrow to discuss these topics beginning at 8:00 a.m. PDT (11:00 a.m. EDT). To participate via telephone, please call 888-463-4487 for domestic callers, or 706-679-5355 for international callers. A telephone replay will be available for 48 hours by dialing 800-642-1687 for domestic callers, or 706-645-9291 for international callers, and entering reservation number 21378327. The conference call will be broadcast live over the Internet at http://www.halozyme.com and will be available for 30 days.

About HYLENEX

HYLENEX recombinant (hyaluronidase human injection) is indicated as an adjuvant to increase the absorption and dispersion of other injected drugs, as an adjuvant for subcutaneous fluid administration (hypodermoclysis), and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents. Hyaluronidase is contraindicated in patients with hypersensitivity to hyaluronidase enzyme or any other ingredients in the formulation. Hyaluronidase should not be used to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs. Discontinue HYLENEX recombinant if sensitization occurs. Hyaluronidase should not be applied directly to the cornea, and should not be injected around infected or ac
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... -- China Cord Blood Corporation (NYSE: CO ) ... results for the first quarter of fiscal year 2015 ... the US.  The Company will host ... August 29, 2014 to discuss its financial performance and ... followed by a question and answer session.  Interested parties ...
(Date:8/21/2014)... VIEW, Calif. , Aug. 21, 2014 /PRNewswire/ ... properties and behaviors based on external stimuli such ... poised to have a disruptive effect in multiple ... revolutionize the business landscape by printing objects ranging ... aerospace and automotive sectors. Logo - ...
(Date:8/21/2014)... 21, 2014 Pursuit Solutions ( ... technology and services for Life Sciences sales and ... Use of New Commercial Sales Models” by Peter ... , The article examines some innovative models used ... being tested in the pharmaceutical market. Robinson grades ...
(Date:8/21/2014)... Bulgaria (PRWEB) August 21, 2014 ... released today by Ontotext . Now the ... semantic analysis of structured and unstructured data is available ... the cost of enterprise technology. Organizations that do not ... for data management can use S4 since there is ...
Breaking Biology Technology:China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4
... YORK, March 21, 2011 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, ... "AOBO"), a pharmaceutical company dedicated to improving health through ... of prescription and over the counter ("OTC") products, announced ... 15, 2010, that its board of directors authorized a ...
... Md., March 21, 2011 United Therapeutics Corporation ... enrollment in its FREEDOM-C(2) registration trial was completed ... a 16-week, multi-center, international, double-blind, randomized, placebo-controlled study ... diethanolamine (UT-15C) in pulmonary arterial hypertension (PAH) patients ...
... Recent events in Japan have caused the world to ... be a cause for concern – especially if radiation ... proliferating cells of the body. Cells of the hematopoietic ... two such cell types. Damage to these cells initiates ...
Cached Biology Technology:American Oriental Bioengineering Announces US$20 Million Share Repurchase Program 2United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial 2Existing Radiation Countermeasures Inadequate! Development of Rx100 Promises Change! 2Existing Radiation Countermeasures Inadequate! Development of Rx100 Promises Change! 3
(Date:8/20/2014)... Aug. 20, 2014 George E. Fox, a John and ... of Houston (UH), was named a fellow in the International ... , Fox is one of four members two ... chosen as fellows in 2014. Fellows are elected every ... more than 500 members from more than 20 countries, the ...
(Date:8/20/2014)... of 158 pregnant teenagers in Rochester, NY, nearly half ... of ice, cornstarch, vacuum dust, baby powder and soap, ... , Moreover, such teens had significantly lower iron levels ... substances. , Pregnant teens, regardless of pica, are at ... iron deficiency and anemia. Low iron in pregnant teens ...
(Date:8/20/2014)... Researchers at Huntsman Cancer Institute (HCI) at the University ... the gene that encodes BCR-ABL, the unregulated enzyme driving ... the American Cancer Society, nearly 6,000 new cases of ... in use, called tyrosine kinase inhibitors (TKIs), target BCR-ABL ... not cure CML but control it in a way ...
Breaking Biology News(10 mins):UH professor named fellow by International Astrobiology Society 2Pica in pregnant teens linked to low iron 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... Even healthy pregnant women can be at risk for ... Reserve University began to understand which bacteria from the 700 ... health problem of preterm and stillbirths. Yiping Han ... Dental Medicine led the study, which found several new bacteria ...
... laboratories, two Dartmouth biologists have performed one of the largest ... population. Their results, published online on May 9 by the ... more important than predation by birds and snakes when it ... Tennyson wrote that nature is ,red in tooth and claw, ...
... May 7, 2010 In findings that advance scientists, ... from The Scripps Research Institute has shed light on a ... other lysosomal storage diseases. The findings were published in ... Biology on May 9, 2010. "This study is ...
Cached Biology News:Even healthy pregnant women need to worry about oral bacteria 2Researchers use entire islands in the Bahamas to test survival of the fittest 2Scripps research scientists shed light on potential treatment for Gaucher's disease 2Scripps research scientists shed light on potential treatment for Gaucher's disease 3Scripps research scientists shed light on potential treatment for Gaucher's disease 4
... The Yeast Whole Genome ChIP-on-chip Microarray ... of yeast (S. cerevisiae) DNA binding ... with Agilent DNA microarrays. This set ... data with greater true binding events ...
... DTT White solid. ... Purity: ≥99% by titration. ... Absorbance: (100 mM, 280 nm):≤0.05. ... or H 2 O. RTECS ...
... pombe Whole Genome ChIP-on-chip Microarray is ... yeast (S. pombe) DNA binding proteins ... Agilent DNA microarrays. This set delivers ... with greater true binding events and ...
... The recent sequencing of Salmonella genomes ... enterica Typhimurium ORFmer PCR* primer pairs. The ... of a single chromosome (4,857,432 bp; 4,440 ... 107 ORFs). These ORFmers from Sigma-Genosys have ...
Biology Products: